Exebacase

Unassigned

New Medicines

Staphylococcal bacteraemia

Information

New molecular entity
ContraFect
ContraFect

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials

Category

Recombinant phage-derived lysin targeting Staphylococci that causes pore formation in bacterial walls resulting in cell lysis
Between April 2017 and March 2018, there were 846 cases of MRSA bacteraemia reported in England [2].
Staphylococcal bacteraemia
Intravenous